Antioxidants and Related Phytochemicals:
Current Scientific Perspective
Stephen Barrett, M.D.
Many "antioxidant" products are marketed with claims that, by blocking the action free radicals, they can help prevent heart disease, cancer, and various other conditions associated with aging. These claims should be regarded with skepticism.
Free radicals are atoms or groups of atoms that have at least one unpaired electron, which makes them highly reactive. Free radicals promote beneficial oxidation that produces energy and kills bacterial invaders. In excess, however, they produce harmful oxidation that can damage cell membranes and cell contents. It is known that people who eat adequate amounts of fruits and vegetables high in antioxidants have a lower incidence of cardiovascular disease, certain cancers, and cataracts. Fruits and vegetables are rich in antioxidants, but it is not known which dietary factors are responsible for the beneficial effects. Each plant contains hundreds of phytochemicals (plant chemicals) whose presence is dictated by hereditary factors. Only well-designed long-term research can determine whether any of these chemicals, taken in a pill, would be useful for preventing any disease.
The most publicized phytochemicals with antioxidant properties have been vitamin C, vitamin E, and beta-carotene (which the body converts into vitamin A). Evidence exists that vitamin E can help prevent atherosclerosis by interfering with the oxidation of low-density lipoproteins (LDL), a factor associated with increased risk of heart disease. However, vitamin E also has an anticoagulant effect that can promote excessive bleeding. In 1993, The New England Journal of Medicine published two epidemiologic studies which found that people who took vitamin E supplements had fewer deaths from heart disease [1,2]. These studies did not prove that taking vitamin E was useful because they did not rule out the effects of other lifestyle factors or consider death rates from other diseases. Moreover, other studies have had conflicting results. The only way to settle the question scientifically is to conduct long-term double-blind clinical studies comparing vitamin users to nonusers and checking death rates from all causes.
Clinical Trials Have Been Disappointing
So far, the results of clinical trials have been mostly negative. The first trial compared the effects of vitamin E (alpha-tocopherol), beta-carotene, and a placebo among heavy smokers. The researchers found no benefit from vitamin E and 18% more lung cancer among those who received beta-carotene. In addition, the overall death rate of beta-carotene recipients was 8% higher, and those who took vitamin E had a higher frequency of hemorrhagic stroke . In 1997, the researchers reported on the effect of vitamin E or beta-carotene on the incidence of heart attacks or death among the subjects who had had a previous heart attack (myocardial infarction). The report covered 1,862 men aged 50 to 69 who were followed for a median of 5.3 years. The men had received dietary supplements of alpha-tocopherol (50 mg/day), beta-carotene (20 mg/day), both, or a placebo. There were significantly more deaths from coronary heart disease among those who took beta-carotene supplements, and a trend toward more deaths (but not enough to be statistically significant) in the vitamin E group .
The second study found no evidence that supplementing with vitamin C, vitamin E, or beta-carotene prevented colorectal cancer . The third study, which followed 22,000 physicians for 12 years, found no difference in cancer or cardiovascular disease rates between users and nonusers of beta-carotene . The fourth trial, which tested a combination of beta-carotene and vitamin A, was terminated after four years because it appeared that the supplement-takers who smoked had a 28% higher incidence of lung cancer and a 17% higher death rate .
In the mid-1990s, a double-blind clinical trial found that taking high doses of vitamins C and E and beta-carotene did not reduce the odds of arteries reclogging after balloon coronary angioplasty. The patients took either probucol (a cholesterol-lowering drug), probucol plus the three antioxidants, the antixoidants alone, or a placebo. More than 200 patients completed the study without protocol violations. Patients in the antioxidant groups received 30,000 IU of beta-carotene, 500 mg of vitamin C, and 700 IU of vitamin E twice daily. All of the patients received aspirin, which is known to reduce the incidence of reclogging. After six months, the rates of repeated angioplasty were 11% in the probucol group, 16.2% in the combined treatment group, 24.4% in the multivitamin group, and 26.6% in the placebo group .
Another study involved 2,545 women and 6,996 men 55 years of age or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor. These patients were randomly assigned to receive either 400 IU of natural vitamin E or a matching placebo for an average of 4.5 years. There were no significant differences in heart attacks, strokes, or death between the vitamin E and placebo groups. The researchers concluded that "In patients at high risk for cardiovascular events, treatment with vitamin E for a mean of 4.5 years has no apparent effect on cardiovascular outcomes." 
Yet another study tested aspirin, vitamin E, and beta-carotene in the prevention of cancer and cardiovascular disease among 39,876 women aged 45 years or older. Among those randomly assigned to receive 50 mg of beta-carotene or a placebo every other day, there were no statistically significant differences in incidence of cancer, cardiovascular disease, or overall death rate after a median of two years of treatment and two years of follow-up .
Charles Hennekens, M.D., a who participated in two of the above studies, has pointed out that even if antioxidants could provide the benefits suggested by epidemiologic studies, smoking cessation and other lifestyle factors would have a far greater effect on the rates of lung cancer and coronary heart disease . In 1998, The Medical Letter concluded:
- The benefits of taking high doses of vitamin E remain to be established.
- There is no convincing evidence that taking supplements of vitamin C prevents any disease.
- No one should take high-dose beta-carotene supplements .
Shortly afterward, a study was published that may explain why very high doses of beta-carotene appeared to increase lung cancer rates among smokers. The study was conducted in ferrets, which metabolize beta-carotene much like humans. Researchers at the Jean Mayer USDA Human Nutrition Research Center at Tufts University reported that excess amounts stored in the lungs became oxidized into substances that decreased a tumor suppressor and increased a tumor promoter in the animals' lungs. The ferrets were divided into four groups. One received beta-carotene and was exposed to cigarette smoke equivalent to a human smoking 1.5 packs per day. Two other groups got either the supplement or smoke exposure, and a control group got neither. The first group had the strongest precancerous changes .
Two studies have found that antioxidants may interfere with the protective action of drugs intended to improve cholesterol levels.
- A 1-year study of 153 patients found that supplements of vitamin C, vitamin E, beta-carotene and selenium may interfere with the ability of simvastatin (Zocor) and niacin to raise the HDL levels of patients with abnormally low HDL levels. The patients receiving antioxidants and drugs had an average HDL increase of 18%, whereas the patients who received drugs alone has a 25% increase. However, HDL2-C, an HDL component thought to account for much of HDL's cardioprotective benefit, rose by 42% with drugs alone but was unchanged in patients who also received antioxidants . Although the study was small, it casts further doubt on the value of antioxidant supplementation .
- A 3-year, double-blind, controlled study of 160 patients with significant coronary artery disease and low HDL levels found that those who received niacin and simvastatin had fewer heart attacks and a slight regression of coronary lesions, as measured by angiography. However, comparable patients who received just antioxidants (vitamins E and C, beta-carotene, and selenium) had no benefit, and patients who received the antioxidants in addition to niacin and simvastatin did worse than those who received niacin and simvastatin alone. The researchers believe that the negative effect resulted from blocking an increase in HDL2 that would have had a cardioprotective effect . An accompanying editorial noted that "although the study completely refute claims that other combinations of antioxidant treatments are useful in distinct populations, the findings add to the growing body of evidence that certain supplemental antioxidant regimes have limited benefit in patients with cardiovascular disease." 
In 1999, the American Heart Association's nutrition committee issued a science advisory discussing relationships between antioxidants and heart disease. The statement concluded:
Considerable evidence now suggests that oxidants are involved in the development and clinical expression of coronary heart disease and that antioxidants may contribute to disease resistance. Consistent with this view is epidemiological evidence indicating that greater antioxidant intake is associated with lower disease risk. Although this increased antioxidant intake generally has involved increased consumption of antioxidant-rich foods, some recent observational studies have suggested the importance of levels of vitamin E intake achievable only by supplementation. There is currently no such evidence from primary prevention trials, but results from secondary prevention trials have shown beneficial effects of vitamin E supplements on some disease end points. In contrast, trials directly addressing the effects of beta-carotene supplements have not shown beneficial effects, and some have suggested deleterious effects, particularly in high-risk population subgroups.
In view of these findings, the most prudent and scientifically supportable recommendation for the general population is to consume a balanced diet with emphasis on antioxidant-rich fruits and vegetables and whole grains. This advice, which is consistent with the current dietary guidelines of the American Heart Association, considers the role of the total diet in influencing disease risk. Although diet alone may not provide the levels of vitamin E intake that have been associated with the lowest risk in a few observational studies, the absence of efficacy and safety data from randomized trials precludes the establishment of population-wide recommendations regarding vitamin E supplementation. In the case of secondary prevention [protection of people known to have coronary artery disease], the results from clinical trials of vitamin E have been encouraging, and if further studies confirm these findings, consideration of the merits of vitamin E supplementation in individuals with cardiovascular disease would be warranted. 
In 2003, researchers at the Cleveland Clinic concluded that long-term supplementation with vitamin E or beta-carotene has not been proven beneficial in preventing cardiovascular disease. To reach this conclusion, they analyzed seven randomized controlled trials of vitamin E treatment and eight of beta-carotene treatment, all of which included at least 1,000 patients. The dosage ranged from 50 to 800 IU for vitamin E and 15 to 50 mg of beta-carotene; and follow-up ranged from 1.4 to 12.0 years. The vitamin E trials involved a total of 81,788 patients, and the beta-carotene trials involved 138,113. Compared with control treatment, Vitamin E did not increase the overall death rate or significantly decrease the risk of cardiovascular death or stroke. Beta-carotene led to a small but significant increase in overall deaths and a slight increase in cardiovascular death. Thus, although epidemiologic evidence has suggested that these antioxidant supplements may be beneficial, clinical trials have found otherwise .
In 2004, after reviewing their results, the American Heart Association Council on Nutrition, Physical Activity, and Metabolism concluded that antioxidants have little or no proven value for preventing or treating cardiovascular disease. The committee found:
- Of nine studies on vitamin E and cardiovascular disease (CVD), five showed no effect on CVD events, three showed beneficial effects, and one showed a negative effect.
- Of four studies of beta-carotene, three showed no effects on CVD and one showed a negative effect.
- Of five studies of antioxidant "cocktails," two showed no effects and three showed negative effects.
- Two studies of vitamins E and C together showed beneficial effects .
In 2007, Cochrane Collaboration team concluded that commonly taken antioxidant supplements may do more harm than good. Their review encompassed 68 randomized controlled trials with 232,606 participants who took various combinations of beta carotene, vitamin A, vitamin C, vitamin E, and/or selenium or a placebo or had no intervention . The reviewers concluded:
- There was no convincing evidence that antioxidant supplements have beneficial effects on overall death rate.
- In 47 trials with 180,938 participants, the antioxidant supplements significantly increased the death rate.
- Beta carotene, vitamin A, and vitamin E given singly or combined with other antioxidant supplements significantly increase mortality
- The potential roles of vitamin C and selenium on mortality need further study.
- Considering that 10% to 20% of the adult population in North America and Europe may consume the assessed supplements, the public health consequences may be substantial.
- Because the study examined only the influence of synthetic antioxidants, its findings should not be applied to the potential effects of eating fruits and vegetables.
In 2014, the U.S. Preventive Services Task Force examined whether dietary supplements were useful in preventing cardiovascular disease or cancer. The Task Force concluded that there was insufficient scientific evidence to assess the balance of benefits and harms of taking multivitamins but recommended against taking beta carotene or vitamin E supplements .
In 2018, Canadian researchers who assessed the literature from 2012 to 2017 to judge whether antioxidant supplements could prevent or treat cardiovascular disease concluded:
Antioxidant mixtures did not appear to benefit cardiovascular disease but might increase all-cause mortality. In the absence of further studies, the current data on supplement use reinforce advice to focus on healthy dietary patterns, with an increased proportion of plant foods in which many of these required vitamins and minerals can be found .
Antioxidants for Macular Degeneration?
Research has also looked at whether taking supplements or eating foods rich in antioxidants can protect against age-related macular degeneration (AMD), a disease in which the central portion of the retina deteriorates so that only peripheral vision remains. A team of Australian researchers who followed 3,654 subjects age 49 or older found no statistically significant association between AMD and dietary intake of either carotene, zinc, or vitamins A or C, either from diet, supplements, or both . Other published studies have had conflicting results, with some finding correlations and others finding none.
The most elaborate study is the Age-Related Eye Disease Study (AREDS), an 11-center clinical trial cosponsored by the National Eye Institute and Bausch & Lomb. In 2001, the researchers reported on what had happened to about 3600 study participants aged 55 to 80 who had been followed for an average of 6.3 years. Patients received either high doses of antioxidants (vitamin C 500 mg, vitamin E 400 IU, beta-carotene 15 mg); 80 mg of zinc oxide; the antioxidants plus zinc; or a placebo. No benefit was found in patients with a relatively small probability of AMD progression. When these patients were excluded from the analysis, the estimated probability of developing advanced AMD was 28% with placebo, 23% with antioxidants alone, 22% with zinc alone, and 20% with both zinc and antioxidants. The authors concluded that patients at high risk for AMD progression "should consider taking a supplement of antioxidants plus zinc such as that used in this study." 
Despite the negative findings of most of the clinical trials, many manufacturers continue to market antioxidants as though they have been proven beneficial. Many also hype mixtures of beta-carotene and other carotenoids, which, they suggest, may provide the same benefits as fruits and vegetables.
Many types of pills described as "concentrates" of fruits and/or vegetables are being marketed. However, it is not possible to condense large amounts of produce into a pill without losing fiber, nutrients, and many other phytochemicals . Although some products contain significant amounts of nutrients, these nutrients are readily obtainable at lower cost from foods.
Since publication of the 2001 AREDS report, many dietary supplements have been marketed through the Internet to ""promote" and/or "preserve" healthy vision. The most widely promoted product is Bausch and Lomb's Ocuvite PreserVision, which contains the amounts of beta carotene, vitamin C, vitamin E, and zinc oxide, used in the study. However, The Medical Letter has cautioned that (a) the magnitude of the reported effect was "modest"; (b) no data suggest any benefit for people who do not have AMD or who have only mild disease; and (c) the increased death rate from lung cancer in smokers who took beta carotene in other studies is evidence enough that high doses of vitamins and minerals are not necessarily harmless." 
In 2002, Pharmanex began promoting its BioPhotonic Scanner for measuring "the antioxidant level in the body" when a person's hand is placed in front of the device. The test is said to measure carotenoid level. Shortly after its availability was announced, I took the company's online "BioScan Quiz," which asked questions about my diet and supplement intake. I found that no matter what answers I gave, I was advised to get scanned and to start using one of the company's antioxidant products, which are quite expensive. As far as I know, however, neither the scan nor the products have been proven to lead to improved health outcomes. I believe that both the scan and the products are a waste of money.
The Bottom Line
There is widespread scientific agreement that eating adequate amounts of fruits and vegetables can help lower the incidence of cardiovascular disease and certain cancers. With respect to antioxidants and other phytochemicals, the key question is whether supplementation has been proven to do more good than harm. So far, the answer is no, which is why the FDA will not permit any of these substances to be labeled or marketed with claims that they can prevent disease.
- Stampfer MJ and others. Vitamin consumption and the risk of coronary disease in women. New England Journal of Medicine 328:1444-1449, 1993.
- Rimm EB and others. Vitamin consumption and the risk of coronary disease in men. New England Journal of Medicine 328:1450-1456, 1993.
- Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine 330:1029-1035, 1994.
- Rapola JM and others. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 349:1715-1720, 1997.
- Greenberg ER and others. A clinical trial of antioxidant vitamins to prevent colorectal cancer. New England Journal of Medicine 331:141-147, 1994.
- Hennekens CH and others. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New England Journal of Medicine 334:1145-1149, 1996.
- Omenn GS and others. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New England Journal of Medicine 334:1150-1155, 1996.
- Tardif J-C. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. New England Journal of Medicine 337:365-372, 1997.
- The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. New England Journal of Medicine 342:145-153, 2000.
- Lee IM and others. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. Journal of the National Cancer Institute 91:2102-2106, 1999.
- Hennekens CH and others. Antioxidant vitamins: Benefits not yet proved. New England Journal of Medicine 330:1080-1081, 1994.
- Vitamin supplements. The Medical Letter on Drugs and Therapeutics 40:75-77, 1998.
- Russel R and others. Why megadoses of beta carotene may promote lung cancer. USDA Agricultural Research Service Food & Nutrition Research Briefs, Jan 1999, p. 1.
- Cheung MC and others. Antioxidant supplements block the response of HDL to Simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arteriosclerosis, Thrombosis, and Vascular Biology 21:1320-1326, 2001.
- Kuller LH. A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arteriosclerosis, Thrombosis, and Vascular Biology 21:1253, 2001.
- Brown BG and others. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine 345:1583-1592, 2001.
- Freedman JE. Antioxidant versus lipid-altering therapy: Some answers, more questions. New England Journal of Medicine 345:1636-1637, 2001.
- Tribble DL and others. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and beta-carotene. American Heart Association Science Advisory. Circulation 99:591-595, 1999.
- Vivekananthan, DP and others. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet 361:2017-2023, 2003.
- Kris-Etherton PM and others. Antioxidant vitamin supplements and cardiovascular disease. Circulation 110:637ñ641, 2004.
- Bjelakovic G and others. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA 297:842-857, 2007.
- Moyer VA and others. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 160:558-564, 2014.
- Jenkins DJA. Supplemental vitamins and minerals for CVD prevention and treatment. Journal of the American College of Cardiology 71:2570-2584, 2018.
- Smith W and others. Dietary oxidants and age-related maculopathy: The Blue Mountains Study. Ophthalmology 106:761-767, 1999.
- Age-Related Eye Disease Study Research Group (AREDS). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology 119:1417-1436, 2001.
- Phytochemicals. Drugstore in a salad? Consumer Reports on Health 7:133-135, 1995.
- Antioxidant vitamins and zinc for macular degeneration. The Medical Letter 45:45-46, 2003.